Torrent Pharmaceuticals has delivered a solid set of numbers for the quarter ending June 2025. The company reported sales of ₹3,178 crore, marking an 11% year-on-year growth. Operating profit (EBITDA) came in at ₹1,032 crore, up 14%, showing improved efficiency and margin strength. Net profit jumped 20% YoY to ₹548 crore, reflecting better cost control and strong execution. Earnings per share (EPS) also rose sharply to ₹16.19, compared to ₹13.50 in the same quarter last year. The company is maintaining strong financial health, with a market cap of ₹1.22 lakh crore and a PE ratio of 60.7, indicating robust investor confidence. With steady revenue growth and expanding profits, Torrent Pharma continues to strengthen its position in the pharma space.

#PersonalFinance#StockInNews#FundamentalViews#MacroViews#Miscellaneous

781 likes·69 comments